Synergistic effects of GS-1101 and Doxorubicin in acute lymphoblastic leukemia cell line
| Autor: | Ava Safaroghli-Azar, Parisa Sadreazami, Forouzan Bahmani, Davood Bashash |
|---|---|
| Jazyk: | English<br />Persian |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Mazandaran University of Medical Sciences, Vol 27, Iss 153, Pp 28-38 (2017) |
| Druh dokumentu: | article |
| ISSN: | 1735-9260 1735-9279 |
| Popis: | Background and purpose: Interest into targeting PI3K in cancer has increased by the recent disclosure that aberrant activity of PI3K/Akt signaling pathway is associated with disease recurrence and poor outcome in different malignancies. The aim of this study was to investigate the potentiating effect of PI3K inhibitor, GS-1101 on doxorubicin-induced cell death in acute lymphoblastic leukemia-derived, Nalm-6 cells. Materials and methods: In this experimental study, to evaluate whether abrogating PI3K/Akt pathway using GS-1101 could enhance cytotoxic effect of doxorubicin in acute lymphoblastic leukemia, Nalm-6 pre-B ALL cells were subjected to combination treatment and subsequent cell viability. Then cell count, metabolic activity, and transcriptional alteration of apoptosis-related target genes were investigated using Trypan blue exlussion, MTT and Rq-PCR analysis, respectively. Results: Our data delineated that GS-1101 augments doxorubicin-induced cytotoxic and its anti-proliferative effect, as evidenced by the decreased cell survival, cellular metabolic activity, and reduction in the number of inhibitor-treated viable cells. Moreover, real-time PCR analysis revealed that induction of cell death by the drug combination was associated with increased Bax transcriptional activity (P≤0.01) followed by the elevated molecular ratio of Bax/Bcl-2 (P≤0.001). Conclusion: This study suggested that abrogation of the PI3K pathway using GS-1101 could potentiate doxorubicin-induced anti-leukemic activity. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|